JP7850366B2 - アビラテロンプロドラッグ - Google Patents

アビラテロンプロドラッグ

Info

Publication number
JP7850366B2
JP7850366B2 JP2023514424A JP2023514424A JP7850366B2 JP 7850366 B2 JP7850366 B2 JP 7850366B2 JP 2023514424 A JP2023514424 A JP 2023514424A JP 2023514424 A JP2023514424 A JP 2023514424A JP 7850366 B2 JP7850366 B2 JP 7850366B2
Authority
JP
Japan
Prior art keywords
abiraterone
patient
pharmaceutical composition
decanoate
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023514424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539371A5 (https=
JP2023539371A (ja
Inventor
マシュー， ジェイ． シャープ，
ウィリアム， アール．， ジュニア ムーア，
Original Assignee
アステラス ユーエス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アステラス ユーエス エルエルシー filed Critical アステラス ユーエス エルエルシー
Publication of JP2023539371A publication Critical patent/JP2023539371A/ja
Publication of JP2023539371A5 publication Critical patent/JP2023539371A5/ja
Application granted granted Critical
Publication of JP7850366B2 publication Critical patent/JP7850366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023514424A 2020-09-02 2021-09-01 アビラテロンプロドラッグ Active JP7850366B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073502P 2020-09-02 2020-09-02
US63/073,502 2020-09-02
PCT/US2021/048607 WO2022051330A1 (en) 2020-09-02 2021-09-01 Abiraterone prodrugs

Publications (3)

Publication Number Publication Date
JP2023539371A JP2023539371A (ja) 2023-09-13
JP2023539371A5 JP2023539371A5 (https=) 2024-09-05
JP7850366B2 true JP7850366B2 (ja) 2026-04-23

Family

ID=77951832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514424A Active JP7850366B2 (ja) 2020-09-02 2021-09-01 アビラテロンプロドラッグ

Country Status (9)

Country Link
US (1) US20240050447A1 (https=)
EP (1) EP4208171A1 (https=)
JP (1) JP7850366B2 (https=)
CN (1) CN116490165A (https=)
AU (1) AU2021338271A1 (https=)
CA (1) CA3189989A1 (https=)
IL (1) IL300837A (https=)
MX (1) MX2023002478A (https=)
WO (1) WO2022051330A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
WO2024107928A1 (en) 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116287275B (zh) * 2023-04-10 2024-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用
WO2025240673A1 (en) * 2024-05-15 2025-11-20 Cardiff Oncology, Inc. Cancer treatment using akt inhibitors and plk1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20121788A1 (it) * 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
WO2014111815A2 (en) * 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
CN104017045B (zh) * 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US10722527B2 (en) * 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
EP3394080B1 (en) * 2015-12-23 2023-06-07 The University Of British Columbia Lipid-linked prodrugs
CN106977577A (zh) * 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US11957696B2 (en) * 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
JP2024533332A (ja) * 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤
CA3243913A1 (en) * 2022-03-01 2023-09-07 Astellas Us Llc Abiraterone prodrugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ

Also Published As

Publication number Publication date
CN116490165A (zh) 2023-07-25
EP4208171A1 (en) 2023-07-12
US20240050447A1 (en) 2024-02-15
MX2023002478A (es) 2023-03-27
JP2023539371A (ja) 2023-09-13
WO2022051330A1 (en) 2022-03-10
IL300837A (en) 2023-04-01
CA3189989A1 (en) 2022-03-10
AU2021338271A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
JP7850366B2 (ja) アビラテロンプロドラッグ
US11957696B2 (en) Abiraterone prodrugs
JP7644713B2 (ja) アビラテロンプロドラッグ
US20250025417A1 (en) Oral abiraterone formulations
US20250186463A1 (en) Abiraterone decanoate prodrugs and use in therapy
RU2822219C2 (ru) Пролекарства абиратерона
HK40096900A (zh) 阿比特龙前药
HK40096901A (zh) 阿比特龙前药
HK40120426A (zh) 阿比特龙前药
WO2024107928A1 (en) Abiraterone decanoate composition and use in therapy
HK40130201A (zh) 阿比特龙前药
HK40065545B (zh) 阿比特龙前药
HK40065545A (en) Abiraterone prodrugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20260312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324

R150 Certificate of patent or registration of utility model

Ref document number: 7850366

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150